These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33665638)

  • 1. Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients.
    Aslostovar L; Boyd AL; Benoit YD; Di Lu J; Garcia Rodriguez JL; Nakanishi M; Porras DP; Reid JC; Mitchell RR; Leber B; Xenocostas A; Foley R; Bhatia M
    Cell Rep Med; 2021 Feb; 2(2):100202. PubMed ID: 33665638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.
    Aslostovar L; Boyd AL; Almakadi M; Collins TJ; Leong DP; Tirona RG; Kim RB; Julian JA; Xenocostas A; Leber B; Levine MN; Foley R; Bhatia M
    Blood Adv; 2018 Aug; 2(15):1935-1945. PubMed ID: 30093531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
    Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
    Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
    Kikushige Y; Miyamoto T
    Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
    Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
    Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
    Kikushige Y; Miyamoto T
    Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
    Haubner S; Perna F; Köhnke T; Schmidt C; Berman S; Augsberger C; Schnorfeil FM; Krupka C; Lichtenegger FS; Liu X; Kerbs P; Schneider S; Metzeler KH; Spiekermann K; Hiddemann W; Greif PA; Herold T; Sadelain M; Subklewe M
    Leukemia; 2019 Jan; 33(1):64-74. PubMed ID: 29946192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
    Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
    Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.
    Dietrich PA; Yang C; Leung HH; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY
    Blood; 2014 Nov; 124(22):3284-94. PubMed ID: 25293777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia.
    Zhou H; Jiang Y; Huang Y; Zhong M; Qin D; Xie C; Pan G; Tan J; Deng M; Zhao H; Zhou Y; Tang Y; Lai Q; Fang Z; Luo Y; Jiang Y; Xu B; Zha J
    Cancer Lett; 2023 Feb; 554():215997. PubMed ID: 36396101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 12. CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.
    Gluexam T; Grandits AM; Schlerka A; Nguyen CH; Etzler J; Finkes T; Fuchs M; Scheid C; Heller G; Hackl H; Harrer N; Sill H; Koller E; Stoiber D; Sommergruber W; Wieser R
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
    Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.
    Zhang L; Nguyen LXT; Chen YC; Wu D; Cook GJ; Hoang DH; Brewer CJ; He X; Dong H; Li S; Li M; Zhao D; Qi J; Hua WK; Cai Q; Carnahan E; Chen W; Wu X; Swiderski P; Rockne RC; Kortylewski M; Li L; Zhang B; Marcucci G; Kuo YH
    Nat Commun; 2021 Oct; 12(1):6154. PubMed ID: 34686664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
    Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
    Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
    Wang A; Zhong H
    Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.
    Verhagen HJMP; van Gils N; Martiañez T; van Rhenen A; Rutten A; Denkers F; de Leeuw DC; Smit MA; Tsui ML; de Vos Klootwijk LLE; Menezes RX; Çil M; Roemer MGM; Vermue E; Heukelom S; Zweegman S; Janssen JJWM; Ossenkoppele GJ; Schuurhuis GJ; Smit L
    Cell Rep; 2018 Dec; 25(11):3021-3035.e5. PubMed ID: 30540936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thioridazine requires calcium influx to induce MLL-AF6-rearranged AML cell death.
    Tregnago C; Da Ros A; Porcù E; Benetton M; Simonato M; Simula L; Borella G; Polato K; Minuzzo S; Borile G; Cogo P; Campello S; Massi A; Romagnoli R; Buldini B; Locatelli F; Pigazzi M
    Blood Adv; 2020 Sep; 4(18):4417-4429. PubMed ID: 32931582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.